Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies.
Secretory clusterin (sCLU) is a potential prognostic tumour biomarker, but results of different sCLU studies are inconsistent. We conducted this meta-analysis to evaluate the precise predictive value of sCLU. Qualified studies were identified by performing online searches in PubMed, EMBASE, and Web...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4988765?pdf=render |
| _version_ | 1818597274622623744 |
|---|---|
| author | Jianzhong Zhang Chenkui Miao Aiming Xu Kai Zhao Zhiqiang Qin Xiao Li Chao Liang Yibo Hua Wei Chen Chao Zhang Yiyang Liu Shifeng Su Zengjun Wang Bianjiang Liu |
| author_facet | Jianzhong Zhang Chenkui Miao Aiming Xu Kai Zhao Zhiqiang Qin Xiao Li Chao Liang Yibo Hua Wei Chen Chao Zhang Yiyang Liu Shifeng Su Zengjun Wang Bianjiang Liu |
| author_sort | Jianzhong Zhang |
| collection | DOAJ |
| description | Secretory clusterin (sCLU) is a potential prognostic tumour biomarker, but results of different sCLU studies are inconsistent. We conducted this meta-analysis to evaluate the precise predictive value of sCLU. Qualified studies were identified by performing online searches in PubMed, EMBASE, and Web of Science. The selected articles were divided into three groups based on scoring method for clusterin detection. Pooled hazard ratios (HRs) with 95% confidence interval (CI) for patient survival and disease recurrence were calculated to determine the correlation between sCLU expression and cancer prognosis. Heterogeneity was assessed using I2 statistics, and specific heterogeneity in different groups was analysed. Elevated sCLU was significantly associated with recurrence-free survival in groups 1 and 3 (group 1: pooled HR = 1.35, 95% CI = 1.01 to 1.79; group 3: pooled HR = 1.80, 95% CI = 1.22 to 2.65). However, clusterin expression was not associated with overall survival in all three groups. Results showed that only the heterogeneity of group 2 was very strong (p = 0.013, I2 = 76.3%), in which the specimens were scored through sCLU staining intensity only. sCLU is a potential biomarker for tumour prognosis, and IHC methods can be more standardised if both intensity and staining proportion are considered. |
| first_indexed | 2024-12-16T11:45:12Z |
| format | Article |
| id | doaj.art-234b15517349465db2ea2631e4ea54bd |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T11:45:12Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-234b15517349465db2ea2631e4ea54bd2022-12-21T22:32:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016115010.1371/journal.pone.0161150Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies.Jianzhong ZhangChenkui MiaoAiming XuKai ZhaoZhiqiang QinXiao LiChao LiangYibo HuaWei ChenChao ZhangYiyang LiuShifeng SuZengjun WangBianjiang LiuSecretory clusterin (sCLU) is a potential prognostic tumour biomarker, but results of different sCLU studies are inconsistent. We conducted this meta-analysis to evaluate the precise predictive value of sCLU. Qualified studies were identified by performing online searches in PubMed, EMBASE, and Web of Science. The selected articles were divided into three groups based on scoring method for clusterin detection. Pooled hazard ratios (HRs) with 95% confidence interval (CI) for patient survival and disease recurrence were calculated to determine the correlation between sCLU expression and cancer prognosis. Heterogeneity was assessed using I2 statistics, and specific heterogeneity in different groups was analysed. Elevated sCLU was significantly associated with recurrence-free survival in groups 1 and 3 (group 1: pooled HR = 1.35, 95% CI = 1.01 to 1.79; group 3: pooled HR = 1.80, 95% CI = 1.22 to 2.65). However, clusterin expression was not associated with overall survival in all three groups. Results showed that only the heterogeneity of group 2 was very strong (p = 0.013, I2 = 76.3%), in which the specimens were scored through sCLU staining intensity only. sCLU is a potential biomarker for tumour prognosis, and IHC methods can be more standardised if both intensity and staining proportion are considered.http://europepmc.org/articles/PMC4988765?pdf=render |
| spellingShingle | Jianzhong Zhang Chenkui Miao Aiming Xu Kai Zhao Zhiqiang Qin Xiao Li Chao Liang Yibo Hua Wei Chen Chao Zhang Yiyang Liu Shifeng Su Zengjun Wang Bianjiang Liu Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. PLoS ONE |
| title | Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. |
| title_full | Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. |
| title_fullStr | Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. |
| title_full_unstemmed | Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. |
| title_short | Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. |
| title_sort | prognostic role of secretory clusterin in multiple human malignant neoplasms a meta analysis of 26 immunohistochemistry studies |
| url | http://europepmc.org/articles/PMC4988765?pdf=render |
| work_keys_str_mv | AT jianzhongzhang prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT chenkuimiao prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT aimingxu prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT kaizhao prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT zhiqiangqin prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT xiaoli prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT chaoliang prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT yibohua prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT weichen prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT chaozhang prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT yiyangliu prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT shifengsu prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT zengjunwang prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies AT bianjiangliu prognosticroleofsecretoryclusterininmultiplehumanmalignantneoplasmsametaanalysisof26immunohistochemistrystudies |